Skip to content

Study · Animal study (in vivo) · mouse · 2016

6 results

[COMPARISON OF PHARMACOLOGICAL EFFECTS OF HEPTAPEPTIDE SELANK AFTER INTRANASAL AND INTRAPERITONEAL ADMINISTRATION TO BALB/c AND C57BL/6 MICE.]

Vasil'eva EV, Kondrakhin EA, Salimov RM, Kovalev GI

Eksperimental'naia i klinicheskaia farmakologiia1 Jan 2016

PMID29787664 (opens in a new tab)PepBankPUB-29787664
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, selank given intraperitoneally or intranasally had an anxiolytic effect only in BALB/c mice, not in C57BL/6 mice.

    In plain wordsIn mice, selank reduced anxiety-type behavior only in the BALB/c strain, by either route, and not in the C57BL/6 strain.

    Peptide
    Selank
    Outcome
    MixedAnxiolytic effect in elevated plus maze
    Study

    mousen: not reported in source

    BALB/c and C57BL/6 mice
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    300 μg/kg/day · intraperitoneal and intranasal · 5 daysAs given in this study (mouse).

    Source sentences

    Summary
    The anxiolytic and nootropic efficiency of selank administered via both routes was observed only in BALB/c mice, which were characterized by initially reduced exploratory activity and higher levels of anxiety as compared to C57BL/6 mice.
    1 context sentence
    Summary · context
    Pharmacological effects of intraperitoneal (i.p.) and intranasal (i.n.) administration of heptapeptide selank (300 μg/kg/day for 5 days), known to possess anxiolytic and nootropic properties, were compared by studying the elevated-plus-maze behavior of inbred BALB/c and C57BL/6 mice and measuring th…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, selank given intraperitoneally or intranasally had a nootropic effect only in BALB/c mice, not in C57BL/6 mice.

    In plain wordsIn mice, selank's memory-enhancing effect was seen only in the BALB/c strain, by either route, and not in the C57BL/6 strain.

    Peptide
    Selank
    Outcome
    MixedNootropic effect
    Study

    mousen: not reported in source

    BALB/c and C57BL/6 mice
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    300 μg/kg/day · intraperitoneal and intranasal · 5 daysAs given in this study (mouse).

    Source sentences

    Summary
    The anxiolytic and nootropic efficiency of selank administered via both routes was observed only in BALB/c mice, which were characterized by initially reduced exploratory activity and higher levels of anxiety as compared to C57BL/6 mice.
    1 context sentence
    Summary · context
    Pharmacological effects of intraperitoneal (i.p.) and intranasal (i.n.) administration of heptapeptide selank (300 μg/kg/day for 5 days), known to possess anxiolytic and nootropic properties, were compared by studying the elevated-plus-maze behavior of inbred BALB/c and C57BL/6 mice and measuring th…
  3. 03AnimalAnimal study (in vivo)Mechanism

    In BALB/c mice, intraperitoneal selank increased the number of GABA-receptor binding sites in the frontal cortex by 38%.

    In plain wordsIn BALB/c mice, selank given into the abdomen raised the number of GABA receptor binding sites in the frontal cortex by 38%.

    Peptide
    Selank
    Outcome
    IncreaseGABA receptor binding sites in frontal cortex (i.p.)
    Study

    mousen: not reported in source

    BALB/c mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    300 μg/kg/day · intraperitoneal · 5 daysAs given in this study (mouse).

    Measurements

    GABA receptor binding sites increase
    38%
    frontal cortex, BALB/c, i.p.

    Source sentences

    Summary
    In BALB/c mice, i.p. selank increased the number of [G-(3)H]SR 95531 binding sites with GABA-receptors in the frontal cortex by 38%
    1 context sentence
    Summary · context
    Pharmacological effects of intraperitoneal (i.p.) and intranasal (i.n.) administration of heptapeptide selank (300 μg/kg/day for 5 days), known to possess anxiolytic and nootropic properties, were compared by studying the elevated-plus-maze behavior of inbred BALB/c and C57BL/6 mice and measuring th…
  4. 04AnimalAnimal study (in vivo)Mechanism

    In BALB/c mice, intraperitoneal selank did not change binding to NMDA receptors in the hippocampus.

    In plain wordsIn BALB/c mice, selank given into the abdomen did not change NMDA receptor binding in the hippocampus.

    Peptide
    Selank
    Outcome
    No significant changeNMDA receptor binding in hippocampus (i.p.)
    Study

    mousen: not reported in source

    BALB/c mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    300 μg/kg/day · intraperitoneal · 5 daysAs given in this study (mouse).

    Source sentences

    Summary
    without change in binding to NMDA receptors in the hippocampus
    1 context sentence
    Summary · context
    Pharmacological effects of intraperitoneal (i.p.) and intranasal (i.n.) administration of heptapeptide selank (300 μg/kg/day for 5 days), known to possess anxiolytic and nootropic properties, were compared by studying the elevated-plus-maze behavior of inbred BALB/c and C57BL/6 mice and measuring th…
  5. 05AnimalAnimal study (in vivo)Mechanism

    In BALB/c mice, intranasal selank increased the density of [3H]MK-801 binding sites by 23%.

    In plain wordsIn BALB/c mice, selank given through the nose raised the density of NMDA-type MK-801 binding sites by 23%.

    Peptide
    Selank
    Outcome
    IncreaseMK-801 (NMDA) binding site density (i.n.)
    Study

    mousen: not reported in source

    BALB/c mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    300 μg/kg/day · intranasal · 5 daysAs given in this study (mouse).

    Measurements

    MK-801 binding site density increase
    23%
    intranasal, BALB/c

    Source sentences

    Summary
    In BALB/c mice, i.p. selank increased the number of [G-(3)H]SR 95531 binding sites with GABA-receptors in the frontal cortex by 38%, without change in binding to NMDA receptors in the hippocampus. On the contrary, i.n. selank led to an increase in the density of [G-(3)H]MK-801 binding sites by 23% w…
    1 context sentence
    Summary · context
    Pharmacological effects of intraperitoneal (i.p.) and intranasal (i.n.) administration of heptapeptide selank (300 μg/kg/day for 5 days), known to possess anxiolytic and nootropic properties, were compared by studying the elevated-plus-maze behavior of inbred BALB/c and C57BL/6 mice and measuring th…
  6. 06AnimalAnimal study (in vivo)Mechanism

    In BALB/c mice, intranasal selank had no effect on GABA receptors.

    In plain wordsIn BALB/c mice, selank given through the nose had no effect on GABA receptors.

    Peptide
    Selank
    Outcome
    No significant changeGABA receptor binding (i.n.)
    Study

    mousen: not reported in source

    BALB/c mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    300 μg/kg/day · intranasal · 5 daysAs given in this study (mouse).

    Source sentences

    Summary
    In BALB/c mice, i.p. selank increased the number of [G-(3)H]SR 95531 binding sites with GABA-receptors in the frontal cortex by 38%, without change in binding to NMDA receptors in the hippocampus. On the contrary, i.n. selank led to an increase in the density of [G-(3)H]MK-801 binding sites by 23% w…
    1 context sentence
    Summary · context
    Pharmacological effects of intraperitoneal (i.p.) and intranasal (i.n.) administration of heptapeptide selank (300 μg/kg/day for 5 days), known to possess anxiolytic and nootropic properties, were compared by studying the elevated-plus-maze behavior of inbred BALB/c and C57BL/6 mice and measuring th…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.